🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Prothrombin Complex Concentrate, Human

    The First People's Hospital of Lianyungang

    Cardiac Surgical Procedures

    approved small molecule active

    1 trial

  2. Proton Pump Inhibitors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Upper Gastrointestinal Hemorrhage

    approved small molecule active

    1 trial

  3. Qianjin Capsule of Gynaecology

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pelvic Inflammatory Diseases

    approved small molecule active

    1 trial

  4. Qizhitongluo Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    approved small molecule completed

    1 trial

  5. Quick-Acting Heart Reliever

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Stenosis

    approved small molecule completed

    1 trial

  6. Rabbit ATG, (Genzyme)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aplastic Anemia

    approved small molecule active

    1 trial

  7. Raltitrexed

    The First People's Hospital of Lianyungang

    Head and Neck Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  8. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  9. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  10. Recaticimab and Statin

    The First People's Hospital of Lianyungang

    Intracranial Atherosclerosis

    approved small molecule active

    1 trial

  11. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  12. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial

  13. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial

  14. Recombinant human growth hormone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Achondroplasia

    approved small molecule active

    1 trial

  15. Recombinant human growth hormone (r-hGH)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dwarfism, Pituitary

    approved small molecule completed

    1 trial

  16. Recombinant staphylokinase

    The First People's Hospital of Lianyungang

    ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  17. Recombinant tissue plasminogen activator (rt-PA)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Thromboembolisms

    approved small molecule active

    1 trial

  18. Regimen:TDF+3TC+EFV

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hiv

    approved small molecule completed

    1 trial

  19. Regimen：BIC+FTC+TAF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV Infection

    approved small molecule active

    1 trial

  20. Regiocit solution pour hémofiltration

    Pari Pharma GmbH

    Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.

    approved small molecule active

    1 trial

  21. Rematazolam Besylate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Emergence Agitation

    approved small molecule active

    1 trial

  22. Remifentanil

    Hospital Authority, Hong Kong

    Labor Pain

    approved small molecule active

    1 trial

  23. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial

  24. Renin-angiotensin system blockers

    Hospital Authority, Hong Kong

    Diabetes

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources